Luis Paz-Ares
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (50)
Year:
2026
Effective strategies to reinvigorate the immune system are needed to improve outcomes in small cell lung cancer (SCLC). Targeting Src family kinases with dasatinib (Dasa) can elicit immunomodulatory effects in some cancer types. In this study, we explored the potential of combining Dasa with immune checkpoint blockade in SCLC. Although the SCLC models were refractory to anti–PD-1 or anti-CTLA4 monotherapy, anti–PD-1 and anti-CTLA4 combination immunotherapy (ITc) induced a significant antitumor response. Furthermore, the Dasa + ITc combination was superior to ITc or Dasa alone. Dasa + ITc activity was mediated by CD4 + T cells, MHC-II+ antigen-presenting cells, and NK cells, as depletion of these populations impeded the combination treatment antitumor efficacy. Increased tumor infiltration of CD4 + and CD8 + T cells, NK cells, M1-like macrophages, and CD11c + antigen-presenting cells and a reduction of regulatory T cells and M2-like macrophages were found in Dasa + ITc–treated mice. Dasa increased CCL5 in NK cells and reduced regulatory T-cell conversion from CD4 + lymphocytes. Dasa + ITc therapy elicited robust antitumor efficacy in three-dimensional cocultures of immune and SCLC cells. In vivo experiments showed that CCL5 was necessary for the Dasa + ITc response. In immunotherapy-treated patients with SCLC, a gene signature including CD4, CIITA, and tumor mutational burden predicted good prognosis. On-treatment CCL5 plasma levels were increased only in patients with long progression-free survival, and pretreatment secretomics identified cytokines related to myeloid cells significantly associated with poor prognosis. In summary, combining Dasa with immunotherapy represents a strategy to treat SCLC, with CCL5 as a cytokine that could serve to monitor response. Significance: Multikinase inhibitor and immune checkpoint blockade combination therapy overcomes the immunosuppressive tumor microenvironment in small cell lung cancer by activating CCL5 and costimulating CD4 + T cells, NK cells, and MHC-II + cells.
Year:
2025
Oncogene amplification and tumour suppressor deletion can drive tumour initiation, progression and treatment resistance. Detection at diagnosis often signals poor prognosis, but it can also enable opportunities for treatment with highly effective targeted therapies. Predicting the likelihood that a patient will acquire these driver alterations in the future using a genomic test represents an opportunity to realise the benefits of interventions earlier, potentially with preventative intent. Here, we present a forecasting framework that takes as input a DNA copy number profile and predicts whether the tumour will acquire an oncogene amplification or tumour suppressor deletion in the future. This framework leverages mutation rate estimates from the input tumour, alongside gene-specific selection coefficients derived from a large cohort of 7,880 tumours. We demonstrate feasibility using 7,042 single-time-point samples and longitudinally collected tumour pairs from 44 prostate and 100 lung cancers, identifying tumours that went on to acquire amplifications at a later time point with an average AUC of 0.87. We show potential clinical utility by forecasting poor prognosis in low-grade gliomas via CDK4/PDGFRA amplification or CDKN2A deletion, and osimertinib resistance in lung cancers via MET amplification. This study serves as a proof-of-concept for a new class of biomarker, wherein selective pressures and mutation-generating processes can be harnessed to anticipate future genomic alterations.
Year:
2025
Immunotherapy resistance in non–small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can be shaped by the mutational landscape of the tumor. Here, we observed genetic alterations in the PTEN/PI3K/AKT/mTOR pathway and/or loss of PTEN expression in >25% of patients with NSCLC, with higher frequency in lung squamous carcinomas (LUSC). Patients with PTEN-low tumors had higher levels of PD-L1 and PD-L2 and showed worse progression-free survival when treated with immunotherapy. Development of a Pten -null LUSC mouse model revealed that tumors with PTEN loss were refractory to antiprogrammed cell death protein 1 (anti–PD-1), highly metastatic and fibrotic, and secreted TGFβ/CXCL10 to promote conversion of CD4 + lymphocytes into regulatory T cells (Treg). Human and mouse PTEN-low tumors were enriched in Tregs and expressed higher levels of immunosuppressive genes. Importantly, treatment of mice bearing Pten -null tumors with TLR agonists and anti-TGFβ antibody aimed to alter this immunosuppressive microenvironment and led to tumor rejection and immunologic memory in 100% of mice. These results demonstrate that lack of PTEN causes immunotherapy resistance in LUSCs by establishing an immunosuppressive tumor microenvironment that can be reversed therapeutically. Significance: PTEN loss leads to the development of an immunosuppressive microenvironment in lung cancer that confers resistance to anti–PD-1 therapy, which can be overcome by targeting PTEN loss–mediated immunosuppression.
Year:
2025
Subgroup analysis of PFS by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events.
Year:
2024
Relationship between PD-L1 expression and tTMB score. (A) Box plots showing the distribution of tTMB score in patients by PD-L1 subgroup; (B) Venn diagram showing overlap between the tTMB ≥10 mut/Mb and PD-L1 TC or IC ≥1% subgroups. Percentages are calculated from the PD-L1 and tTMB BEP, i.e., patients who had both a PD-L1 and a tTMB result (n=275); samples from 171 patients had tTMB ≥10 mut/Mb and/or PD-L1 TC or IC ≥1%, while samples from 104 patients (37.8%) had both tTMB
Year:
2024
Subgroup analysis of PFS by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events.
Year:
2024
Subgroup analysis of confirmed ORR by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses.
Year:
2024
Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms.
Year:
2024
Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus tremelimumab plus EP versus EP and (B) durvalumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (32)
Paul A. Bunn
Distinguished Professor
University of Colorado Cancer Center
Marina Garassino
Prof
Università degli Studi di Torino
Alvaro González
Head Department
Clinica Universidad de Navarra
Javier García-Corbacho
Head of Early Drug Development Unit
-
Syed Hussain
Professor of Medical Oncology
University of Sheffield Medical School
Bartomeu Massuti
Head Department
Istituto Europeo di Oncologia
Kai He
The Ohio State University Wexner Medical Center
Charles Rudin
Memorial Sloan Kettering Cancer Center
Alfonso Calvo
Catedrático
Universidad de Navarra
Jonathan W. Goldman
Associate Professor
UCLA
Patricia Mondelo-Macía
-
Amanda Parkes
University of Wisconsin-Madison
Santiago Ponce Aix
Head of Therapeutic Innovation and Precision Medicine
Hospital Universitario 12 de Octubre
Diego Serrano
Universidad de Navarra
Geoff Macintyre
Group leader
Centro Nacional de Investigaciones Oncológicas
Alvaro Ucero
Assistant Professor
Universidad Complutense de Madrid
Anthony M. Joshua
Head of Department
University Health Network
Oscar Juan-Vidal
-
Juan José Lasarte
Professsor
Universidad de Navarra
Ramon Amat Ferrer
Senior Scientist
Vall d´Hebron Institute of Oncology
Luis Alvarez-Vallina
Group Leader and Director of the Advanced Therapy Programme
Institut Hospital del Mar d'Investigacions Mèdiques
Maxime Tarabichi
Group Leader
Université libre de Bruxelles
Hossein Borghaei
Professor and Chief, Thoracic Oncology
Fox Chase Cancer Center
Mariano Provencio Pulla
Head of Medical Oncology Department at Puerta de Hierro University Hospital
Hospital Universitario Puerta del Hierro Majadahonda
Eva Maria Garrido Martin
Profesor Ayudante Doctor Biología Celular
-
Javier De Castro
Scientific Director
La Paz University Hospital
Philipp J Jost
Chairman
Medical University of Graz
Esther Conde
Hospital Universitario 12 de Octubre
Giorgia Foggetti
Project leader
Ospedale San Raffaele
ENRIQUETA FELIP
Head Thoracic Oncology Unit (After Competitive Exam)
Hospital Universitari Vall d'Hebron
Rossana Berardi
Associate Professor
Università Politecnica delle Marche
Afshin Dowlati
-
Make your next move.
Prepare your application
Review drafts before you send them.